Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095540 | 0.91 | HRH3 (0.54) | HRH3LTA4HALDH1A1RECQLCYSLTR1 | |
| SCHEMBL17478267 | 0.89 | HRH3 (0.53) | HRH3LTA4HALDH1A1CYSLTR1MEN1 | |
| SCHEMBL11649743 | 0.86 | HRH3 (0.56) | HRH3LTA4HALDH1A1RECQLCYSLTR1 | |
| SCHEMBL16902877 | 0.84 | HRH3 (0.59) | HRH3LTA4HALDH1A1RECQLCYSLTR1 | |
| SCHEMBL8545935 | 0.84 | HRH3 (0.59) | HRH3LTA4HCYSLTR1CYP2D6ACHE | |
| SCHEMBL5636691 | 0.83 | KCNA3 (0.46) | LTA4HALDH1A1RECQL | |
| SCHEMBL16902880 | 0.82 | HRH3 (0.58) | HRH3LTA4HALDH1A1CYSLTR1MEN1 | |
| SCHEMBL16902868 | 0.82 | HRH3 (0.58) | HRH3LTA4HALDH1A1CYSLTR1MEN1 | |
| SCHEMBL16902883 | 0.82 | HRH3 (0.58) | HRH3LTA4HALDH1A1CYSLTR1MEN1 | |
| SCHEMBL8369936 | 0.82 | HRH3 (0.58) | HRH3LTA4HALDH1A1CYSLTR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018202681-A1 | USE OF DISUBSTITUTED BENZENES TO CONTROL INSECTICIDE-RESISTANT PESTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | WO | disclosed |
| US-9932309-B2 | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2018-04-03 | — | — | US | disclosed |
| US-9932309-B2 | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2018-04-03 | — | — | US | disclosed |
| US-9932309-B2 | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2018-04-03 | — | — | US | disclosed |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| EP-3174872-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | Université de Lille 2 Droit et Santé (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016238-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016238-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2016-02-04 | — | — | WO | disclosed |
| EP-1076558-A1 | 2-PHENYL-1-[-(2-AMINOETHOXY)-BENZYL -INDOLE IN COMBINATION WITH ESTROGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6159959-A | Combined estrogen and antiestrogen therapy | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| US-6127404-A | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)INDOLE COMPOUNDS USEFUL AS ESTROGEN AGONISTS/ANTAGONISTS; OSTEOPOROSIS; ANTICHOLESTEROL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-6107292-A | HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-22 | — | — | US | disclosed |
| US-6069153-A | HORMONE REPLACEMENT THERPAY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| US-5998402-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; ANTICANCER AGENTS;POSTMEMOPAUSE THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999059581-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE IN COMBINATION WITH ESTROGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999058524-A1 | BENZOCARBAZOLE AND INDENOINDOLE DERIVED ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| CN-1170719-A | Estrogenic agents | AMERICAN HOME PROD (US) | 1998-01-21 | — | — | CN | disclosed |
| EP-0802183-A1 | Estrogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | CYP3A5, CYP2D6, QDPR | HRH3 999/4885LTA4H 1668/4885ALDH1A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.